CASP3 and non-small cell lung carcinoma: In other primary (pNSCLC-2 and pNSCLC-3) and established (A549 and NCI-H1944 lines) NSCLC cells, ASP4132 treatment (1 μM, 48 h) significantly increased caspase-3 activity (Fig. 2G) and the apoptotic nuclei ratio (Fig. 2H).